Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 710,000 | 0% |
| Operating expense | 35M | 2.8% |
| Net Income | -32M | 4.3% |
| EBITDA | -32M | 11.7% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 272M | 3.6% |
| Total Liabilities | 39M | 80.3% |
| Total Equity | 233M | 10.5% |
| Shares Outstanding | 58M | 0% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -32M | 10.4% |
| Cash from investing | 52M | 9.9% |
| Cash from financing | 3,000 | 0% |
EPS
Financial Highlights for Astria Therapeutics in Q3 '25
Astria Therapeutics reported a revenue of 710,000, which is a 0% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. Stable revenue suggests consistent sales performance, but it's beneficial to examine other financial metrics and industry trends for a comprehensive view.
Operating Expenses for this period were 35M, showing a -2.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -32M, showing a 4.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -32M, showing a 11.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
